Truist Securities Reiterates Buy Rating on Pfizer (PFE) Following ReViral Acquisition, Sees is "Potential Return to M&A"
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $62.00 price target on Pfizer (NYSE: PFE), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
